Jupiter Neurosciences Inc. Common Stock (JUNS)

FairStock Score: 10/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings power, honest accounting, and a margin of safety. Jupiter Neurosciences does not fit that mold today. It is a clinical-stage CNS and rare-disease company with only five employees, two segments, and no profits. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was just $24,245 while net loss was $2.3M. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $18,652 and net loss was $2.1M. For fiscal year 2025, period ended 2025-12-31, revenue was $21,796 and net loss was $8.6M. Those are not the numbers of a compounder; they are the numbers of a venture-style research effort. Growth is essentially nonexistent, and the provided profit growth figure of -0.95% does nothing to change that.

In plain English: Jupiter Neurosciences is a small healthcare company trying to develop treatments for brain and nervous-system diseases, and it also sells nutritional supplements. It brings in very little money and loses millions of dollars, so the business looks weak on its current numbers. At $3.36 a share, the price does not look cheap compared with the tiny revenue and continuing losses, and much of the value depends on whether its experimental drugs work.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer